Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
CRNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.10 - $62.53
Previous CloseN/A
Volume214.21K
Average Volume (3M)945.11K
Market Cap
$2.91B
Enterprise Value$1.55B
Total Cash (Recent Filing)$1.20B
Total Debt (Recent Filing)$49.94M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 06, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding94,175,995
10 Day Avg. Volume920,707
30 Day Avg. Volume945,111
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue1.11K
Enterprise Value/Gross Profit-10.41K
Enterprise Value/Ebitda-3.69
Forecast
1Y Price Target
$71.09Price Target Upside133.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Market PotentialCrinetics is positioned to shift from a late-stage development company to a fully integrated commercial organization.
Product AdvantageMany called paltusotine a game-changer in acromegaly compared to the current standard-of-care.
Product LaunchThe company continues to prepare for its first commercial launch of Palsonify to treat acromegaly ahead of the PDUFA target action date.
Bears Say
CompetitionPaltusotine's lead indication is acromegaly where SRLs are SOC, but fail to provide durable disease control and require painful injections.
Regulatory ApprovalCrinetics is approaching its September 25 PDUFA for Palsonify (paltusone) in acromegaly, following NDA acceptance in December of last year on the back of positive Phase 3 PATHFNDR-1 and PATHFNDR-2 results.
Safety ConcernsManagement reiterated comfort in atumelnant’s safety profile, despite a single case of AST/ALT elevations in the 120mg cohort, citing the growing body of clinical experience.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $24.10 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $2.91B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 70 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.082 by -$0.148.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -1.23.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 94,175,995 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.082. Following the earnings report the stock price went down -3.694%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Currently, no hedge funds are holding shares in CRNX
Crinetics Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.09 (133.85% Upside)
$71.09 (133.85% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 411.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.77%
12-Months-Change
Fundamentals
Return on Equity
-36.94%
Trailing 12-Months
Asset Growth
37.84%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for rare endocrine diseases and other unmet medical needs. The company operates primarily in the biotechnology sector, concentrating on the discovery and development of small molecule drugs that target specific receptor pathways. Its core products include investigational drugs such as paltusotine, aimed at treating conditions like acromegaly and Cushing's disease, as well as other pipeline candidates addressing various hormonal disorders.
CRNX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant progress in regulatory approvals, commercial launch preparations, and pipeline development. Financial health remains strong despite increased operating expenses. However, challenges in achieving immediate launch uptake were noted.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$71.09
▲(133.85% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Ownership Overview
2.08% Insiders
40.59% Mutual Funds
37.53% Other Institutional Investors
3.35% Public Companies and
Individual Investors